Lexicon Pharmaceuticals, Inc. (LXRX)Healthcare | Biotechnology | The Woodlands, United States | NasdaqCM
2.29 USD
-0.03
(-1.293%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.31 +0.02 (0.852%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:32 a.m. EDT
The investment case here is severely compromised by a collapsing business model. The company is hemorrhaging cash, with operating cash flow and free cash flow both deeply negative, while revenue has cratered by nearly 98% year-over-year. The balance sheet, though currently bolstered by a massive cash pile relative to debt, cannot sustain this burn without further dilution or capital raises. Fundamentally, this is a value trap; the low price reflects the reality that the core business is dying, not a bargain opportunity. The stock has lost over 92% of its value over the last nine years, with the most recent annual period seeing another sharp decline. There is no dividend to provide income, and the lack of growth makes any turnaround speculative at best. While the options market is placing a heavy bet on the $2.00 level holding as a support zone, suggesting a potential bounce or consolidation rather than an immediate crash, the underlying fundamentals offer no reason for a sustained recovery. This remains a high-risk speculative vehicle suitable only for investors willing to accept the possibility of total capital loss. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.076983 |
| AutoETS | 0.078781 |
| AutoARIMA | 0.079521 |
| AutoTheta | 0.169559 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.375 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 33.944 |
| Revenue per Share | 0.106 |
| Market Cap | 1,018,949,056 |
| Forward P/E | -12.01 |
| Beta | 1.04 |
| Profit Margins | -147.38% |
| Website | https://www.lexpharma.com |
As of Aug. 22, 2026, 3:32 a.m. EDT: Speculators are positioning defensively with heavy put open interest at the $2.00 strike across multiple expirations, acting as a hard floor. While there is some call volume near the money, the dominance of downside protection suggests traders expect volatility or a continued grind lower rather than a breakout. Implied volatility is elevated, pricing in significant uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0714285 |
| Address1 | 2,445 Technology Forest Boulevard |
| Address2 | 11th Floor |
| All Time High | 344.75 |
| All Time Low | 0.28 |
| Ask | 2.6 |
| Ask Size | 1 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 2,422,490 |
| Average Daily Volume3 Month | 3,293,695 |
| Average Volume | 3,293,695 |
| Average Volume10Days | 2,422,490 |
| Beta | 1.035 |
| Bid | 2.29 |
| Bid Size | 2 |
| Book Value | 0.392 |
| City | The Woodlands |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.29 |
| Current Ratio | 13.367 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.32 |
| Day Low | 2.26 |
| Debt To Equity | 33.944 |
| Display Name | Lexicon Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -54,023,000 |
| Ebitda Margins | -1.30273 |
| Enterprise To Ebitda | -16.43 |
| Enterprise To Revenue | 21.403 |
| Enterprise Value | 887,580,096 |
| Eps Current Year | -0.16632 |
| Eps Forward | -0.1906 |
| Eps Trailing Twelve Months | -0.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 281 863 8088 |
| Fifty Day Average | 2.3128 |
| Fifty Day Average Change | -0.022799969 |
| Fifty Day Average Change Percent | -0.009858168 |
| Fifty Two Week Change Percent | 107.14285 |
| Fifty Two Week High | 2.68 |
| Fifty Two Week High Change | -0.3900001 |
| Fifty Two Week High Change Percent | -0.14552243 |
| Fifty Two Week Low | 1.03 |
| Fifty Two Week Low Change | 1.26 |
| Fifty Two Week Low Change Percent | 1.223301 |
| Fifty Two Week Range | 1.03 - 2.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 955,114,200,000 |
| Float Shares | 218,985,063 |
| Forward Eps | -0.1906 |
| Forward P E | -12.01469 |
| Free Cashflow | -44,774,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Fullday Change | -0.03 |
| Fullday Change Percent | -1.2931 |
| Fullday Price | 2.3095 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.86023 |
| Gross Profits | 35,673,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01118 |
| Held Percent Institutions | 0.83688 |
| Implied Shares Outstanding | 444,955,934 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.lexpharma.com/investors/index.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,432,166,400 |
| Last Split Factor | 1:7 |
| Long Business Summary | Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. |
| Long Name | Lexicon Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,018,949,056 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_30781 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -61,116,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,036,747,326 |
| Number Of Analyst Opinions | 5 |
| Open | 2.3 |
| Operating Cashflow | -64,988,000 |
| Operating Margins | -38.3526 |
| Payout Ratio | 0.0 |
| Peg Ratio | -13.77 |
| Phone | 281 863 3000 |
| Post Market Change | 0.019500017 |
| Post Market Change Percent | 0.8515291 |
| Post Market Price | 2.3095 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 2.32 |
| Price Eps Current Year | -13.768639 |
| Price Hint | 4 |
| Price To Book | 5.841837 |
| Price To Sales Trailing12 Months | 24.571344 |
| Profit Margins | -1.47378 |
| Quick Ratio | 13.073 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.2931 |
| Regular Market Day High | 2.32 |
| Regular Market Day Low | 2.26 |
| Regular Market Day Range | 2.26 - 2.32 |
| Regular Market Open | 2.3 |
| Regular Market Previous Close | 2.32 |
| Regular Market Price | 2.29 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 2,677,171 |
| Return On Assets | -0.14324 |
| Return On Equity | -0.40213 |
| Revenue Growth | -0.976 |
| Revenue Per Share | 0.106 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 444,955,934 |
| Shares Percent Shares Out | 0.0736 |
| Shares Short | 32,749,669 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 32,730,919 |
| Short Name | Lexicon Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1387 |
| Short Ratio | 11.53 |
| Source Interval | 15 |
| State | TX |
| Symbol | LXRX |
| Target High Price | 6.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 3.856 |
| Target Median Price | 3.1 |
| Total Cash | 190,610,000 |
| Total Cash Per Share | 0.428 |
| Total Debt | 59,241,000 |
| Total Revenue | 41,469,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.7634 |
| Two Hundred Day Average Change | 0.5266 |
| Two Hundred Day Average Change Percent | 0.29862767 |
| Type Disp | Equity |
| Volume | 2,677,171 |
| Website | https://www.lexpharma.com |
| Zip | 77,381 |